Get the Stockscreener App
76.06
0.03%
0.00
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $76.06, with a volume of 2.40M.
It is up +0.03% in the last 24 hours and down -2.46% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$76.06
Open:
$75.96
24h Volume:
2.40M
Relative Volume:
0.15
Market Cap:
$190.96B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.07
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-5.41%
1M Performance:
-2.46%
6M Performance:
-21.19%
1Y Performance:
-42.01%
1-Day Range:
$75.69
$76.74
1-Week Range:
$73.31
$78.55
52-Week Range:
$73.31
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
76.05 | 201.96B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
749.38 | 678.30B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
151.89 | 370.87B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
183.62 | 335.74B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
109.75 | 215.19B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
65.92 | 300.99B | 43.59B | 15.04B | 10.74B | 3.3766 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck: Phase 3 trial begins in esophageal cancer - marketscreener.com
Breakthrough Cancer Drug Enters Phase 3 Trial: Merck Targets Deadly Esophageal Cancer with 15% Survival Rate - Stock Titan
Merck: progress report in hypertension (PAH) - marketscreener.com
Merck to Present New Clinical and Outcomes Research Data at The - GuruFocus
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer - Clinical Trials Arena
[Pfizer Inc, AstraZeneca, Merck & Co. Inc] Breakthroughs In Bladder Cancer Treatment Market Research 2025 - openPR.com
Merck & Co., Inc. (NYSE:MRK) Earns “Neutral” Rating from Citigroup - Defense World
Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK) - Defense World
Merck Continues to Deliver Growth in Turbulent Times - chemeurope.com
Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers - insights.citeline.com
Decoding Merck & Co's Options Activity: What's the Big Picture? - Nasdaq
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With KeytrudaMerck & Co (NYSE:MRK) - Benzinga
Why Merck & Co., Inc. (MRK) Is Among the Best Cheap Stocks to Buy Now for Beginners - Insider Monkey
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Merck & Co., Inc. (MRK): One of the Best Dividend Growth Stocks with High Yields - Insider Monkey
Jefferies not seeing significant impact to Merck, Bristol from draft guidance - Yahoo Finance
Merck brings another big business to small town De Soto - NewsBreak: Local News & Alerts
Merck's (MRK) Keytruda Hits Milestone in Ovarian Cancer Trial - GuruFocus
Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer - MSN
Merck (MRK) Achieves Key Milestones in Ovarian Cancer Trial with KEYTRUDA | MRK Stock News - GuruFocus
Merck stock rises as Keytruda succeeds in ovarian cancer (MRK) - Seeking Alpha
Merck’s Keytruda shows promise in ovarian cancer trial - Investing.com
The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech - Yahoo Finance
Merck secures FDA approval for Welireg to treat rare tumours - World Pharmaceutical Frontiers
13 Best Cheap Stocks to Invest in for Beginners - Insider Monkey
Top Analyst Reports for Oracle, IBM & Merck - MSN
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) - BioSpace
Merck (MRK) Gains FDA Approval for Welireg in Treating Rare Tumo - GuruFocus
US FDA expands use of Merck's cancer drug for adrenal gland tumors - Reuters
Merck Gets FDA Approval for Welireg to Treat Rare Tumors - marketscreener.com
FDA Approves Merck'S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL) - marketscreener.com
Transcript : Merck & Co., Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors - Yahoo Finance
FDA Approves Merck's (MRK) Welireg for Rare Tumor Treatment - GuruFocus
Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting - Yahoo Finance
Merck wins FDA label expansion for Welireg (MRK:NYSE) - Seeking Alpha
FDA Approves Merck's (MRK) Welireg for PPGL Treatment | MRK Stoc - GuruFocus
Assessing Merck & Co: Insights From 4 Financial Analysts - Benzinga
Germany's Merck drops China surcharge on orders after US-China tariff deal - NewsBreak: Local News & Alerts
Merck & Co (MRK) Faces Downgrade and Price Target Reduction by C - GuruFocus
Citi cuts Merck stock rating to neutral, slashes target to $84 - Investing.com
Citi cuts Merck stock rating to neutral, slashes target to $84 By Investing.com - Investing.com India
Analyst recommendations: AbbVie, KKR, Merck, Toast, Uber… - marketscreener.com
Merck (MRK) Sees Downgrade as Growth Challenges Loom | MRK Stock News - GuruFocus
Merck Animal Health Investing $895M in US Manufacturing and R&D Facilities - Powder & Bulk Solids
Is Merck & Co. (MRK) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? - Insider Monkey
Merck, JNJ, Bristol , and Other Big Pharma Stocks Counted on a Price Negotiation Loophole. It May Be Closing. - Barron's
Merck & Co. (MRK) Shows Bullish Option Activity as Volatility Ri - GuruFocus
Merck invests $895M in Kansas manufacturing and research facilities - Feedstuffs
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen - Zacks Investment Research
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.98%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):